Офтальмохирургия. 2013; : 111-115
АНГИОГЕНЕЗ ПРИ ПРОЛИФЕРАТИВНОЙ ДИАБЕТИЧЕСКОЙ РЕТИНОПАТИИ: ПЕРСПЕКТИВЫ АНТИ-VEGF-ТЕРАПИИ (ОБЗОР ЛИТЕРАТУРЫ)
https://doi.org/undefinedАннотация
Реферат VEGF-опосредованный ангиогенез является ведущим механизмом патологической неоваскуляризации сетчатки при пролиферативной диабетической ретинопатии (ПДР). Анти-VEGF-терапия может рассматриваться как перспективный метод лечения данного осложнения. У больных с ПДР сочетание анти-VEGF-препаратов с панретинальной лазеркоагуляцией препятствует снижению остроты зрения, развитию макулярного отека и, по некоторым данным, усиливает регресс неоваскуляризации. Введение анти-VEGF-препаратов перед витрэктомией у больных с кровоизлияниями в стекловидное тело уменьшает вероятность повторного кровотечения в витреальную полость во время и после операции. При ПДР, осложненной неоваскулярной глаукомой, интравитреальное введение бевацизумаба приводит к регрессу неоваскуляризации радужки и переднего угла глаза. В настоящее время наибольший объем данных накоплен по применению бевацизумаба, менее изучены эффекты ранибизумаба и пегаптаниба, начаты исследования афлиберцепта. В будущих исследованиях предстоит определить необходимую длительность анти-VEGF-терапии, предикторы ее эффективности и оптимальные сочетания с другими методами лечения ПДР.
Список литературы
1. Повещенко А.Ф., Коненков В.И. Механизмы и факторы ангиогенеза // Успехи физиол. наук.– 2010.– Т. 41, № 2.– P. 68-89.
2. Шадричев Ф.Е., Шкляров Е.Б., Григорьева Н.Н. Использование анти-VEGF терапии в лечении диабетического макулярного отека // Офтальмолог. ведо- мости.– 2011.– Т. IV, № 1.– С. 83-93.
3. Arevalo J.F., Maia M., Flynn H.W. Jr. et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy // Br. J. Ophthalmol.– 2008.– Vol. 92, № 2.– P. 213-216.
4. Avery R.L., Pearlman J., Pieramici D.J. et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy // Ophthalmology.– 2006.– Vol. 113, № 10.– P. e1-e15.
5. Brouzas D., Charakidas A., Moschos M. et al. Bevacizumab (Avastin) for the management of anterior chamber neovascularization and neovascular glaucoma // Clin. Ophthalmol.– 2009.– Vol. 3.– P. 685-688.
6. Brunner S., Schernthaner G.H., Satler M. et al. Correlation of different circulating endothelial progenitor cells to stages of diabetic retinopathy: first in vivo data // Invest. Ophthalmol. Vis. Sci.– 2009.– Vol. 50, № 1.– P. 392-398.
7. Butler J.M., Guthrie S.M., Koc M. et al. SDF-1 is both necessary and sufficient to promote proliferative retinopathy // J. Clin. Invest.– 2005.– Vol. 115, № 1.– P. 86-93.
8. Caballero S., Sengupta N., Afzal A. et al. Ischemic vascular damage can be repaired by healthy, but not diabetic, endothelial progenitor cells // Diabetes.– 2007.– Vol. 56, № 4.– P. 960-967.
9. Cho W.B., Oh S.B., Moon J.W., Kim H.C. Panretinal photocoagulation combined with intravitreal bevacizumab in highrisk proliferative diabetic retinopathy // Retina.– 2009.– Vol. 29, № 4.– P. 516-522.
10. Ciftci S., Sakalar Y.B., Unlu K. et al. Intravitreal bevacizumab combined with panretinal photocoagulation in the treatment of open angle neovascular glaucoma // Eur. J. Ophthalmol.– 2009.– Vol. 19, № 6.– P. 1028-1033.
11. Di Lauro R., De Ruggiero P., di Lauro R. et al. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy // Graefes Arch. Clin. Exp. Ophthalmol.– 2010.– Vol. 248, № 6.– P. 785-791.
12. Diabetic Retinopathy Clinical Research Network. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy // JAMA Ophthalmol.– 2013.– Vol. 131, № 3.– P. 283-293.
13. Filho J.A., Messias A., Almeida F.P. et al. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy // Acta Ophthalmol.– 2011.– Vol. 89, № 7.– P. e567-e572.
14. González V.H., Giuliari G.P., Banda R.M., Guel D.A. Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy // Br. J. Ophthalmol.– 2009.– Vol. 93, № 11.– P. 1474-1478.
15. Hasanreisoglu M., Weinberger D., Mimouni K. et al. Intravitreal bevacizumab as an adjunct treatment for neovascular glaucoma // Eur. J. Ophthalmol.– 2009.– Vol. 19, № 4.– P. 607-612.
16. Hernández C., Simó R. Erythropoietin produced by the retina: its role in physiology and diabetic retinopathy // Endocrine.– 2012.– Vol. 41, № 2.– P. 220-226.
17. Higashide T., Murotani E., Saito Y. et al. Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma // Graefes Arch. Clin. Exp. Ophthalmol.– 2012.– Vol. 250, № 4.– P. 603-610.
18. Hornan D., Edmeades N., Krishnan R. et al. Use of pegaptanib for recurrent and non-clearing vitreous haemorrhage in proliferative diabetic retinopathy // Eye.– 2010.– Vol. 24, № 8.– P. 1315-1359.
19. Jorge R., Costa R.A., Calucci D. et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study) // Retina.– 2006.– Vol. 26, № 9.– P. 1006-1013.
20. Li Calzi S., Neu M.B., Shaw L.C., Grant M.B. Endothelial progenitor dysfunction in the pathogenesis of diabetic retinopathy: treatment concept to correct diabetesassociated deficits // EPMA J.– 2010.– Vol. 1, № 1.– P. 88-100.
21. Mirshahi A., Roohipoor R., Lashay A. et al. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial // Eur. J. Ophthalmol.– 2008.– Vol. 18, № 2.– P. 263-269.
22. Moradian S., Ahmadieh H., Malihi M. et al. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy // Graefes Arch. Clin. Exp. Ophthalmol.– 2008.– Vol. 246, № 12.– P. 1699-1705.
23. Nicholson B.P., Schachat A.P. A review of clinical trials of anti-VEGF agents for diabetic retinopathy // Graefes Arch. Clin. Exp. Ophthalmol.– 2010.– Vol. 248.– P. 915-930.
24. Ogata N., Nishikawa M., Nishimura T. et al. Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy // Am. J. Ophthalmol.– 2002.– Vol. 134, № 3.– P. 348-353.
25. Preti R.C., Ramirez L.M., Monteiro M.L. et al. Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a randomised clinical trial // Br. J. Ophthalmol.– 2013.– Vol. 97, № 7.– P. 885-889.
26. Puddu A., Sanguineti R., Durante A. et al. Vascular endothelial growth factor-C secretion is increased by advanced glycation end-products: possible implication in ocular neovascularization // Mol. Vis.– 2012.– Vol. 18.– P. 2509-2517.
27. Rangasamy S., Srinivasan R., Maestas J. et al. A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy // Invest. Ophthalmol. Vis. Sci.– 2011.– Vol. 52, № 6.– P. 3784-3791.
28. Sun J., Xu Y., Sun S. et al. Intermittent high glucose enhances cell proliferation and VEGF expression in retinal endothelial cells: the role of mitochondrial reactive oxygen species // Mol. Cell. Biochem.– 2010.– Vol. 343, № 1-2.– P. 27-35.
29. Tatsumi T., Yamamoto S., Uehara J. et al. Panretinal photocoagulation with simultaneous cryoretinopexy or intravitreal bevacizumab for neovascular glaucoma // Graefes Arch. Clin. Exp. Ophthalmol.– 2013.– Vol. 251, № 5.– P. 1355-1360.
30. Tonello M., Costa R.A., Almeida F.P. et al. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study) // Acta Ophthalmol.– 2008.– Vol. 86, № 4.– P. 385-389.
31. Tongers J., Roncalli J.G., Losordo D.W. Role of endothelial progenitor cells during ischemia-induced vasculogenesis and collateral formation // Microvasc. Res.– 2010.– Vol. 79, № 3.– P. 200-206.
32. Willard A.L., Herman I.M. Vascular complications and diabetes: current therapies and future challenges // J. Ophthalmol. Pablished online – 2012.– Doc.10.1155/2012/ 209538.
33. Yau J.W., Rogers S.L., Kawasaki R. et al. Global prevalence and major risk factors of diabetic retinopathy // Diabetes Care. – 2012.– Vol. 35, № 3.– P. 556-564.
34. Yeh P.T., Yang C.H., Yang C.M. Intravitreal bevacizumab injection for recurrent vitreous haemorrhage after diabetic vitrectomy // Acta Ophthalmol.– 2011.– Vol. 89, № 7.– P. 634-640.
35. Yoshida N., Hisatomi T., Ikeda Y. et al. Intravitreal bevacizumab treatment for neovascular glaucoma: histopathological analysis of trabeculectomy specimens // Graefes Arch. Clin. Exp. Ophthalmol.– 2011.– Vol. 249, № 10.– P. 1547-1552.
36. Zechmeister-Koss I., Huic M. Vascular endothelial growth factor inhibitors (antiVEGF) in the management of diabetic macular oedema: a systematic review // Br. J. Ophthalmol.– 2012.– Vol. 96, № 2.– P. 167- 178.
37. Zehetner C., Kirchmair R., Huber S. et al. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema // Br. J. Ophthalmol.– 2013.– Vol. 97, № 4.– P. 454-459.
38. Zhao L.Q., Zhu H., Zhao P.Q., Hu Y.Q. A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy // Br. J. Ophthalmol.– 2011.– Vol. 95, № 9.– P. 1216-1222.
39. Zhong Y., Li J., Chen Y. et al. Activation of endoplasmic reticulum stress by hyperglycemia is essential for Müller cellderived inflammatory cytokine production in diabetes // Diabetes.– 2012.– Vol. 61, № 2.– P. 492-504.
Fyodorov Journal of Ophthalmic Surgery. 2013; : 111-115
ANGIOGENESIS IN PROLIFERATIVE DIABETIC RETINOPATHY: RERSPECTIVES OF ANTI-VEGF THERAPY (REVIEW OF LITERATURE)
https://doi.org/undefinedAbstract
References
1. Poveshchenko A.F., Konenkov V.I. Mekhanizmy i faktory angiogeneza // Uspekhi fiziol. nauk.– 2010.– T. 41, № 2.– P. 68-89.
2. Shadrichev F.E., Shklyarov E.B., Grigor'eva N.N. Ispol'zovanie anti-VEGF terapii v lechenii diabeticheskogo makulyarnogo oteka // Oftal'molog. vedo- mosti.– 2011.– T. IV, № 1.– S. 83-93.
3. Arevalo J.F., Maia M., Flynn H.W. Jr. et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy // Br. J. Ophthalmol.– 2008.– Vol. 92, № 2.– P. 213-216.
4. Avery R.L., Pearlman J., Pieramici D.J. et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy // Ophthalmology.– 2006.– Vol. 113, № 10.– P. e1-e15.
5. Brouzas D., Charakidas A., Moschos M. et al. Bevacizumab (Avastin) for the management of anterior chamber neovascularization and neovascular glaucoma // Clin. Ophthalmol.– 2009.– Vol. 3.– P. 685-688.
6. Brunner S., Schernthaner G.H., Satler M. et al. Correlation of different circulating endothelial progenitor cells to stages of diabetic retinopathy: first in vivo data // Invest. Ophthalmol. Vis. Sci.– 2009.– Vol. 50, № 1.– P. 392-398.
7. Butler J.M., Guthrie S.M., Koc M. et al. SDF-1 is both necessary and sufficient to promote proliferative retinopathy // J. Clin. Invest.– 2005.– Vol. 115, № 1.– P. 86-93.
8. Caballero S., Sengupta N., Afzal A. et al. Ischemic vascular damage can be repaired by healthy, but not diabetic, endothelial progenitor cells // Diabetes.– 2007.– Vol. 56, № 4.– P. 960-967.
9. Cho W.B., Oh S.B., Moon J.W., Kim H.C. Panretinal photocoagulation combined with intravitreal bevacizumab in highrisk proliferative diabetic retinopathy // Retina.– 2009.– Vol. 29, № 4.– P. 516-522.
10. Ciftci S., Sakalar Y.B., Unlu K. et al. Intravitreal bevacizumab combined with panretinal photocoagulation in the treatment of open angle neovascular glaucoma // Eur. J. Ophthalmol.– 2009.– Vol. 19, № 6.– P. 1028-1033.
11. Di Lauro R., De Ruggiero P., di Lauro R. et al. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy // Graefes Arch. Clin. Exp. Ophthalmol.– 2010.– Vol. 248, № 6.– P. 785-791.
12. Diabetic Retinopathy Clinical Research Network. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy // JAMA Ophthalmol.– 2013.– Vol. 131, № 3.– P. 283-293.
13. Filho J.A., Messias A., Almeida F.P. et al. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy // Acta Ophthalmol.– 2011.– Vol. 89, № 7.– P. e567-e572.
14. González V.H., Giuliari G.P., Banda R.M., Guel D.A. Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy // Br. J. Ophthalmol.– 2009.– Vol. 93, № 11.– P. 1474-1478.
15. Hasanreisoglu M., Weinberger D., Mimouni K. et al. Intravitreal bevacizumab as an adjunct treatment for neovascular glaucoma // Eur. J. Ophthalmol.– 2009.– Vol. 19, № 4.– P. 607-612.
16. Hernández C., Simó R. Erythropoietin produced by the retina: its role in physiology and diabetic retinopathy // Endocrine.– 2012.– Vol. 41, № 2.– P. 220-226.
17. Higashide T., Murotani E., Saito Y. et al. Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma // Graefes Arch. Clin. Exp. Ophthalmol.– 2012.– Vol. 250, № 4.– P. 603-610.
18. Hornan D., Edmeades N., Krishnan R. et al. Use of pegaptanib for recurrent and non-clearing vitreous haemorrhage in proliferative diabetic retinopathy // Eye.– 2010.– Vol. 24, № 8.– P. 1315-1359.
19. Jorge R., Costa R.A., Calucci D. et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study) // Retina.– 2006.– Vol. 26, № 9.– P. 1006-1013.
20. Li Calzi S., Neu M.B., Shaw L.C., Grant M.B. Endothelial progenitor dysfunction in the pathogenesis of diabetic retinopathy: treatment concept to correct diabetesassociated deficits // EPMA J.– 2010.– Vol. 1, № 1.– P. 88-100.
21. Mirshahi A., Roohipoor R., Lashay A. et al. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial // Eur. J. Ophthalmol.– 2008.– Vol. 18, № 2.– P. 263-269.
22. Moradian S., Ahmadieh H., Malihi M. et al. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy // Graefes Arch. Clin. Exp. Ophthalmol.– 2008.– Vol. 246, № 12.– P. 1699-1705.
23. Nicholson B.P., Schachat A.P. A review of clinical trials of anti-VEGF agents for diabetic retinopathy // Graefes Arch. Clin. Exp. Ophthalmol.– 2010.– Vol. 248.– P. 915-930.
24. Ogata N., Nishikawa M., Nishimura T. et al. Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy // Am. J. Ophthalmol.– 2002.– Vol. 134, № 3.– P. 348-353.
25. Preti R.C., Ramirez L.M., Monteiro M.L. et al. Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a randomised clinical trial // Br. J. Ophthalmol.– 2013.– Vol. 97, № 7.– P. 885-889.
26. Puddu A., Sanguineti R., Durante A. et al. Vascular endothelial growth factor-C secretion is increased by advanced glycation end-products: possible implication in ocular neovascularization // Mol. Vis.– 2012.– Vol. 18.– P. 2509-2517.
27. Rangasamy S., Srinivasan R., Maestas J. et al. A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy // Invest. Ophthalmol. Vis. Sci.– 2011.– Vol. 52, № 6.– P. 3784-3791.
28. Sun J., Xu Y., Sun S. et al. Intermittent high glucose enhances cell proliferation and VEGF expression in retinal endothelial cells: the role of mitochondrial reactive oxygen species // Mol. Cell. Biochem.– 2010.– Vol. 343, № 1-2.– P. 27-35.
29. Tatsumi T., Yamamoto S., Uehara J. et al. Panretinal photocoagulation with simultaneous cryoretinopexy or intravitreal bevacizumab for neovascular glaucoma // Graefes Arch. Clin. Exp. Ophthalmol.– 2013.– Vol. 251, № 5.– P. 1355-1360.
30. Tonello M., Costa R.A., Almeida F.P. et al. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study) // Acta Ophthalmol.– 2008.– Vol. 86, № 4.– P. 385-389.
31. Tongers J., Roncalli J.G., Losordo D.W. Role of endothelial progenitor cells during ischemia-induced vasculogenesis and collateral formation // Microvasc. Res.– 2010.– Vol. 79, № 3.– P. 200-206.
32. Willard A.L., Herman I.M. Vascular complications and diabetes: current therapies and future challenges // J. Ophthalmol. Pablished online – 2012.– Doc.10.1155/2012/ 209538.
33. Yau J.W., Rogers S.L., Kawasaki R. et al. Global prevalence and major risk factors of diabetic retinopathy // Diabetes Care. – 2012.– Vol. 35, № 3.– P. 556-564.
34. Yeh P.T., Yang C.H., Yang C.M. Intravitreal bevacizumab injection for recurrent vitreous haemorrhage after diabetic vitrectomy // Acta Ophthalmol.– 2011.– Vol. 89, № 7.– P. 634-640.
35. Yoshida N., Hisatomi T., Ikeda Y. et al. Intravitreal bevacizumab treatment for neovascular glaucoma: histopathological analysis of trabeculectomy specimens // Graefes Arch. Clin. Exp. Ophthalmol.– 2011.– Vol. 249, № 10.– P. 1547-1552.
36. Zechmeister-Koss I., Huic M. Vascular endothelial growth factor inhibitors (antiVEGF) in the management of diabetic macular oedema: a systematic review // Br. J. Ophthalmol.– 2012.– Vol. 96, № 2.– P. 167- 178.
37. Zehetner C., Kirchmair R., Huber S. et al. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema // Br. J. Ophthalmol.– 2013.– Vol. 97, № 4.– P. 454-459.
38. Zhao L.Q., Zhu H., Zhao P.Q., Hu Y.Q. A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy // Br. J. Ophthalmol.– 2011.– Vol. 95, № 9.– P. 1216-1222.
39. Zhong Y., Li J., Chen Y. et al. Activation of endoplasmic reticulum stress by hyperglycemia is essential for Müller cellderived inflammatory cytokine production in diabetes // Diabetes.– 2012.– Vol. 61, № 2.– P. 492-504.
